What is Zacks Research’s Forecast for STERIS Q2 Earnings?

STERIS plc (NYSE:STE) – Stock analysts at Zacks Research raised their Q2 2026 EPS estimates for shares of STERIS in a research report issued on Monday, July 14th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $2.47 for the quarter, up from their previous estimate of $2.46. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q3 2026 earnings at $2.68 EPS, Q4 2026 earnings at $2.89 EPS, FY2026 earnings at $10.44 EPS, Q2 2027 earnings at $2.75 EPS, Q4 2027 earnings at $2.79 EPS and FY2028 earnings at $12.40 EPS.

STE has been the subject of a number of other reports. JMP Securities increased their target price on shares of STERIS from $265.00 to $280.00 and gave the company a “market outperform” rating in a research report on Friday, May 16th. Morgan Stanley raised shares of STERIS from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $260.00 to $276.00 in a research report on Tuesday. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 14th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Monday, April 7th. Finally, Stephens reissued an “overweight” rating and set a $250.00 target price on shares of STERIS in a research report on Thursday, May 15th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $266.50.

STERIS Trading Down 0.6%

NYSE:STE opened at $227.48 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.39 and a current ratio of 1.96. The firm has a market cap of $22.38 billion, a price-to-earnings ratio of 36.69 and a beta of 0.92. STERIS has a 52 week low of $200.98 and a 52 week high of $252.79. The firm has a 50-day moving average price of $238.75 and a two-hundred day moving average price of $226.28.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, May 14th. The medical equipment provider reported $2.74 EPS for the quarter, beating the consensus estimate of $2.59 by $0.15. The firm had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.47 billion. STERIS had a net margin of 11.26% and a return on equity of 14.21%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the business posted $2.58 EPS.

Institutional Trading of STERIS

Several institutional investors and hedge funds have recently bought and sold shares of the company. Cibc World Markets Corp raised its position in shares of STERIS by 16.3% during the 4th quarter. Cibc World Markets Corp now owns 15,569 shares of the medical equipment provider’s stock valued at $3,200,000 after buying an additional 2,181 shares in the last quarter. Counterpoint Mutual Funds LLC purchased a new stake in shares of STERIS during the 4th quarter valued at $275,000. Thrivent Financial for Lutherans raised its position in shares of STERIS by 1,563.4% during the 4th quarter. Thrivent Financial for Lutherans now owns 67,400 shares of the medical equipment provider’s stock valued at $13,855,000 after buying an additional 63,348 shares in the last quarter. Generali Asset Management SPA SGR purchased a new stake in shares of STERIS during the 4th quarter valued at $863,000. Finally, Xponance Inc. raised its position in shares of STERIS by 2.7% during the 4th quarter. Xponance Inc. now owns 13,964 shares of the medical equipment provider’s stock valued at $2,870,000 after buying an additional 368 shares in the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at STERIS

In other STERIS news, CEO Daniel A. Carestio sold 17,626 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $242.56, for a total value of $4,275,362.56. Following the sale, the chief executive officer directly owned 51,385 shares in the company, valued at $12,463,945.60. This represents a 25.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Cary L. Majors sold 12,828 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total transaction of $3,208,026.24. Following the completion of the sale, the senior vice president owned 11,372 shares in the company, valued at $2,843,909.76. This represents a 53.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company’s stock.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 26th. Shareholders of record on Tuesday, June 10th were paid a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 1.00%. The ex-dividend date was Tuesday, June 10th. STERIS’s dividend payout ratio is presently 36.77%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.